Combination of the Immune Modulator Fingolimod with Alteplase in Acute Ischemic Stroke: A Pilot Trial

Circulation

Volumn 132, Issue 12, 2015, Pages 1104-1112

  Zhu, Zilong ^a,b   Fu, Ying ^a   Tian, Decai ^a   Sun, Na ^a   Han, Wei ^a   Chang, Guoqiang ^a   Dong, Yinhua ^c   Xu, Xiaolin ^b   Liu, Qiang ^a,c,d   Huang, Deren ^e   Shi, Fu Dong ^a,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN HUANHU HOSPITAL   (China)

^c TIANJIN FOURTH CENTRAL HOSPITAL   (China)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e Neurology and Neuroscience Associates   (United States)

Author keywords

brain ischemia; edema; hemorrhage; inflammation; thrombolytic therapy

Indexed keywords

ALTEPLASE; FINGOLIMOD; FIBRINOLYTIC AGENT; IMMUNOLOGIC FACTOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FIBRINOLYTIC THERAPY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HERPES VIRUS INFECTION; HUMAN; LEUKOPENIA; LUNG INFECTION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MACULAR EDEMA; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTICENTER STUDY; NEUROIMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY TRACT INFECTION; B LYMPHOCYTE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONVALESCENCE; DOSE RESPONSE; DRUG EFFECTS; EDEMA, CARDIAC; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PILOT STUDY; STROKE; T LYMPHOCYTE; TREATMENT OUTCOME;

B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EDEMA, CARDIAC; FEMALE; FIBRINOLYTIC AGENTS; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PILOT PROJECTS; RECOVERY OF FUNCTION; STROKE; T-LYMPHOCYTES; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84942134485     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.016371     Document Type: Article

References (32)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329. doi: 10.1056/NEJMoa0804656.
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587. doi: 10.1056/NEJM199512143332401
3. NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
4. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, Hommel M. Hemorrhagic transformation in acute ischemic stroke: the MAST-E study: MAST-E Group. Stroke. 1999;30:1326-1332. doi: 10.1161/01. STR.30.7.1326
5. Bang OY, Saver JL, Kim SJ, Kim GM, Chung CS, Ovbiagele B, Lee KH, Liebeskind DS; UCLA-Samsung Stroke Collaborators. Collateral flow averts hemorrhagic transformation after endovascular therapy for acute ischemic stroke. Stroke. 2011;42:2235-2239. doi: 10.1161/STROKEAHA.110.604603.
6. Schwamm LH, Koroshetz WJ, Sorensen AG, Wang B, Copen WA, Budzik R, Rordorf G, Buonanno FS, Schaefer PW, Gonzalez RG. Time course of lesion development in patients with acute stroke: serial diffusion-and hemodynamic-weighted magnetic resonance imaging. Stroke. 1998;29:2268-2276. doi: 10.1161/01.STR.29.11.2268
7. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007;6:258-268. doi: 10.1016/S1474-4422(07)70055-8.
8. Neumann-Haefelin T, Kastrup A, de Crespigny A, Yenari MA, Ringer T, Sun GH, Moseley ME. Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation. Stroke. 2000;31:1965-1972. doi: 10.1161/01.STR.31.8.1965
9. Gaudinski MR, Henning EC, Miracle A, Luby M, Warach S, Latour LL. Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant. Stroke. 2008;39:2765-2768. doi: 10.1161/STROKEAHA.107.512269.
10. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. "Malignant" middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 1996;53:309-315. doi:10.1001/archneur.1996.00550040037012.
11. Álvarez-Sabín J, Maisterra O, Santamarina E, Kase CS. Factors influencing haemorrhagic transformation in ischaemic stroke. Lancet Neurol. 2013;12:689-705. doi: 10.1016/S1474-4422(13)70055-3.
12. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808. doi: 10.1038/nm.2399.
13. Macrez R, Ali C, Toutirais O, Le Mauff B, Defer G, Dirnagl U, Vivien D. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 2011;10:471-480. doi: 10.1016/S1474-4422(11)70066-7.
14. Chamorro Á, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nat Rev Neurol. 2012;8:401-410. doi: 10.1038/nrneurol.2012.98.
15. Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69:759-777. doi: 10.1002/ana.22426.
16. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate: modifiers of lymphocyte migration. N Engl J Med. 2006;355:1088-1091. doi: 10.1056/NEJMp068159.
17. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K, Hla T. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factorinduced vascular permeability. J Biol Chem. 2003;278:47281-47290. doi: 10.1074/jbc.M306896200.
18. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci USA. 2012;109:15930-15935. doi: 10.1073/pnas.1203534109.
19. Hait NC, Wise LE, Allegood JC, O'Brien M, Avni D, Reeves TM, Knapp PE, Lu J, Luo C, Miles MF, Milstien S, Lichtman AH, Spiegel S. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci. 2014;17:971-980. doi: 10.1038/nn.3728.
20. Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, Yan Y, Huang D, Yu C, Shi FD. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 2014;71:1092-1101. doi: 10.1001/jamaneurol.2014.1065.
21. Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, Han W, Xue R, Liu Q, Hao J, Yu C, Shi FD. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci USA. 2014;111:18315-18320. doi: 10.1073/pnas.1416166111.
22. Gupta R, Vora NA, Horowitz MB, Tayal AH, Hammer MD, Uchino K, Levy EI, Wechsler LR, Jovin TG. Multimodal reperfusion therapy for acute ischemic stroke: factors predicting vessel recanalization. Stroke. 2006;37:986-990. doi: 10.1161/01.STR.0000209303.02474.27.
23. Chalela JA, Kang DW, Luby M, Ezzeddine M, Latour LL, Todd JW, Dunn B, Warach S. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol. 2004;55:105-112. doi: 10.1002/ana.10781.
24. Wang X, Tsuji K, Lee SR, Ning M, Furie KL, Buchan AM, Lo EH. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke. 2004;35(suppl 1):2726-2730. doi: 10.1161/01.STR.0000143219.16695.af.
25. Campos F, Qin T, Castillo J, Seo JH, Arai K, Lo EH, Waeber C. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke. 2013;44:505-511. doi: 10.1161/STROKEAHA.112.679043.
26. Cipriani R, Chara JC, Rodríguez-Antiguëdad A, Matute C. FTY720 attenuates excitotoxicity and neuroinflammation. J Neuroinflammation. 2015;12:86. doi: 10.1186/s12974-015-0308-6.
27. Deogracias R, Yazdani M, Dekkers MP, Guy J, Ionescu MC, Vogt KE, Barde YA. Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Proc Natl Acad Sci USA. 2012;109:14230-14235. doi: 10.1073/pnas.1206093109.
28. Di Menna L, Molinaro G, Di Nuzzo L, Riozzi B, Zappulla C, Pozzilli C, Turrini R, Caraci F, Copani A, Battaglia G, Nicoletti F, Bruno V. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol Res. 2013;67:1-9. doi: 10.1016/j.phrs.2012.10.004.
29. Ahmad M, Graham SH. Inflammation after stroke: mechanisms and therapeutic approaches. Transl Stroke Res. 2010;1:74-84. doi: 10.1007/s12975-010-0023-7.
30. Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz T, Austinat M, Nieswandt B, Wiendl H, Stoll G. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood. 2010;115:3835-3842. doi: 10.1182/blood-2009-10-249078.
31. Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, Iwaki T, Okada Y, Iida M, Cua DJ, Iwakura Y, Yoshimura A. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15:946-950. doi: 10.1038/nm.1999.
32. Gan Y, Liu Q, Wu W, Yin JX, Bai XF, Shen R, Wang Y, Chen J, La Cava A, Poursine-Laurent J, Yokoyama W, Shi FD. Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci USA. 2014;111:2704-2709. doi: 10.1073/pnas.1315943111.